For successful labeling, 68Ge/68Ga generator eluate has to be concentrated (from 10 mL or more to less than 1 mL) and to be purified of metallic impurities, especially Fe(III), and 68Ge breakthrough. Anionic, cationic and fractional elution methods are well known. We describe two new methods: (1) a combined cationic–anionic purification and (2) an easy-to-use and reliable cationic purification with NaCl solution. Using the first method, 68Ga from 10 mL generator eluate was collected on a SCX cartridge, then eluted with 1.0 mL 5.5 M HCl directly on an anion exchanger (30 mg AG1X8). After drying with a stream of helium, 68Ga was eluted with 0.4 mL water into the reaction vial. We provide as an example labeling of BPAMD. Using the second method, 68Ga from 10 mL generator eluate was collected on a SCX cartridge, then eluted with a hydrochloric solution of sodium chloride (0.5 mL 5 M NaCl, 12.5 μL 5.5 M HCl) into the reaction vial, containing 40 μg DOTATOC and 0.5 mL 1 M ammonium acetate buffer pH 4.5. After heating for 7 min at 90°C, the reaction was finished. Radiochemical purity was higher than 95% without further purification. No 68Ge breakthrough was found in the final product.
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
Baum RP, Prasad V, Müller D, Schuchardt C, Orlova A, Wennborg A, Tolmachev V, Feldwisch J (2010) Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68 Ga-labeled affibody molecules. J Nucl Med 51:892–897PubMedCrossRefGoogle Scholar
Breeman WA, de Jong M, de Blois E, Bernard BF, Konijnenberg M, Krenning EP (2005) Radiolabeling DOTA-peptides with 68 Ga. Eur J Nucl Med Mol Imaging 32:478–485PubMedCrossRefGoogle Scholar
de Blois E, Sze Chan H, Naidoo C, Prince D, Krenning EP, Breeman WA (2011) Characteristics of SnO2 based 68Ge/68Ga generator and aspects of radiolabeling DOTA-peptides. Appl Radiat Isot 69:308–315PubMedCrossRefGoogle Scholar
Fellner M, Baum RP, Kubcek V, Hermann P, Lukes I, Prasad VFR (2010) PET/CT imaging of osteoblastic bone metastases with 68 Ga-bisphosphonates: first human study. Eur J Nucl Med Mol Imaging 37:834PubMedCrossRefGoogle Scholar
Hnatowich DJ (1975) A method for the preparation and quality control of 68Ga radiopharmaceuticals. J Nucl Med 16:764PubMedGoogle Scholar
Mueller D, Klette I, Wortmann R, Baum RP (2006) Markierung von DOTA-peptiden mit gallium- 68 für die nuklearmedizinische Routinediagnostik. Nuklearmedizin 45:A88–A89Google Scholar
Mueller D, Klette I, Gottschaldt M, Baum RP (2009) Radiolabeling of fragile macroligands with 68Ga. J Labelled Compd Radiopharm 52:477Google Scholar
Prasad V, Baum RP (2010) Biodistribution of the Ga-68 labeled somatostatin analogue DOTA- NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions. Q J Nucl Med Mol Imaging 54:61–67PubMedGoogle Scholar
Rösch F (2011) 68Ge/68Ga- generators—past, present and future. World J Nucl Med 10:26Google Scholar
Sainz-Esteban A, Prasad V, Baum RP (2010) Interesting image. Pancreatic neuroendocrine tumor with involvement of the inferior mesenteric vein diagnosed by Ga-68 DOTA-TATE PET/CT. Clin Nucl Med 35:40–41PubMedCrossRefGoogle Scholar
Tolmachev V, Altai M, Sandström M, Perols A, Eriksson Karlström AH, Boschetti F, Orlova A (2011) Evaluation of a maleimido derivative of NOTA for site-specific labeling of affibody molecules. Bioconjug Chem 22:894–902PubMedCrossRefGoogle Scholar
Zhernosekov KP, Filosofov DV, Baum RP, Aschoff P, Bihl H, Razbash AA, Jahn M, Jennewein M, Rösch F (2007) Processing of generator produced 68 Ga for medical application. J Nucl Med 48:1741–1748PubMedCrossRefGoogle Scholar